Objectives Afro-Caribbean patients are underrepresented in acute myeloid leukemia (AML) outcomes research, and the impact of socioeconomic and structural barriers on survival in this population remains poorly defined. We aimed to characterize clinicopathologic features, treatment utilization, and outcomes among Afro-Caribbean adults with AML treated at an urban safety-net hospital. Methods We conducted a retrospective cohort study of adults diagnosed with AML and treated at a large urban safety-net hospital in Brooklyn, New York, between 2012 and 2022. Demographic, clinical, and treatment variables were abstracted from electronic medical records. Outcomes were summarized descriptively, including treatment intensity, transplant eligibility and receipt, and survival. Results Among 47 patients (median age 66 years), 85% identified as Afro-Caribbean. At presentation, 38% were uninsured. Ten patients (21%) received supportive care only. Among treated patients (n = 37), 78% received intensive anthracycline+cytarabine–based induction chemotherapy. Twenty-seven patients (57%) were considered appropriate candidates for allogeneic transplantation based on disease risk and performance status; however, only 3 (11%) ultimately underwent the procedure. Complete remission was achieved in 51%, with 58% subsequently relapsing. Median progression-free survival was 8 months, and median overall survival was 9 months. Three-year progression-free and overall survival were 12.8% and 17.0%, respectively. Conclusions In this single-center safety-net cohort, long-term survival was limited and receipt of allogeneic transplantation was low despite documented eligibility in more than half of the patients. These findings provide descriptive insight into post-remission therapy patterns in an understudied population and identify areas for further investigation.
Thida et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: